title: 28th Annual JPMorgan Healthcare Conference--Human Genome Sciences and Celgene.
abstract: The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Human Genome Sciences Inc and Celgene Corp. Investigational drugs from Human Genome Sciences, including belimumab (in collaboration with GlaxoSmithKline plc), albinterferon alfa-2b (with Novartis AG), mapatumumab (with Takeda Pharmaceutical Co Ltd) and HGS-1029, and from Celgene, including romidepsin, pomalidomide, apremilast and PDA-001 (Celgene Cellular Therapeutics), are discussed.
authors.affiliation: Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. sophie.gale@thomsonreuters.com
authors.forename: Sophie
authors.initials: S
authors.lastname: Gale
authors.forename: Gary
authors.initials: G
authors.lastname: Croasdell
mesh_terms: D000418:Albumins / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D004345:Drug Industry; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006521:Hepatitis, Chronic / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000418:Albumins; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D015507:Drugs, Investigational; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C531108:albinterferon alfa-2b; C511911:belimumab